🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

10,225 results for “He” Clear

  1. Prograft 5 mg capsules, hard, Prograf 0,5 mg Hartkapseln, Prograf 1 mg Hartkapseln, Frexalimab, Prograft 0,5 mg capsules, hard, Prograft 1 mg capsules, hard, Prograf 5 mg Hartkapseln

    Sanofi-aventis Healthcare Pty Ltd

    Kidney transplant rejection

    phase 3 small molecule active

    1 trial

  2. Prolastin 1000 mg, Pulver und Lösungsmittel zur Her- stellung einer Infusionslösung, Prolastin 5000 mg, Pulver und Lösungsmittel zur Herstellung einer Infusionslösung, Prolastin 4000 mg, Pulver und Lösungsmittel zur Herstellung einer Infusionslösung

    Instituto Grifols S.A.

    Severe Alpha-1 Antitrypsin Deficiency (AATD)

    phase 3 small molecule active

    1 trial

  3. Propranolol

    United Therapeutics Europe Ltd

    Burn

    phase 3 small molecule terminated

    1 trial

  4. Protein C Concentrate (Human) Vapor Heated

    Takeda

    Protein C Deficiency

    phase 3 small molecule completed

    1 trial

  5. Psilocybin

    Compass Therapeutics

    Treatment Resistant Depression

    phase 3 small molecule active

    7 trials

  6. Psilocybin

    Compass Therapeutics

    Major Depressive Disorder

    phase 3 small molecule active

    2 trials

  7. QRX003

    Quoin Pharmaceuticals,

    Netherton Syndrome

    phase 3 small molecule active

    1 trial

  8. QRX003, 4% Lotion

    Quoin Pharmaceuticals,

    Netherton Syndrome

    phase 3 small molecule active

    2 trials

  9. QRX003-2% Lotion

    Quoin Pharmaceuticals,

    Netherton Syndrome

    phase 3 small molecule active

    1 trial

  10. QTORIN 3.9% Rapamycin Anhydrous Gel

    PALVELLA THERAPEUTICS, INC.

    Microcystic Lymphatic Malformation

    phase 3 small molecule active

    1 trial

  11. QTORIN 3.9% rapamycin anhydrous gel

    PALVELLA THERAPEUTICS, INC.

    Pachyonychia Congenita

    phase 3 small molecule completed

    1 trial

  12. QVM149

    Grace Therapeutics

    Asthma

    phase 3 small molecule terminated

    1 trial

  13. R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - reactive arm

    Takeda

    Multiple Myeloma

    phase 3 small molecule active

    1 trial

  14. RAP-219

    Rapport Therapeutics

    Focal Seizure

    phase 3 small molecule active

    2 trials

  15. REGN10933 + REGN10987

    Regeneron UK Limited

    Healthy Participants

    phase 3 small molecule completed

    1 trial

  16. REGN3918

    Regeneron UK Limited

    Paroxysmal Nocturnal Hemoglobinuria

    phase 3 small molecule terminated

    1 trial

  17. REGN7508

    Regeneron UK Limited

    Peripheral Artery Disease (PAD)

    phase 3 small molecule active

    1 trial

  18. REL-1017

    RELMADA THERAPEUTICS, INC.

    Major Depressive Disorder

    phase 3 small molecule completed

    3 trials

  19. REN001

    OnKure Therapeutics

    Primary Mitochondrial Myopathy

    phase 3 small molecule terminated

    2 trials

  20. REOLYSIN

    ONCOLYTICS BIOTECH INC

    Carcinoma, Squamous Cell of the Head and Neck

    phase 3 mab completed

    2 trials

  21. RESPIRATORY SYNCYTIAL VIRUS VACCINES

    The George Institute

    RSV infection

    phase 3 small molecule active

    1 trial

  22. REX-001

    Lxo Ireland Designated Activity Company

    Peripheral Arterial Disease (PAD)

    phase 3 small molecule terminated

    2 trials

  23. RHB-105

    RedHill Biopharma

    Helicobacter Pylori Infection

    phase 3 small molecule completed

    1 trial

  24. RIFADINE 300 mg, gélule, ANSATIPINE 150 mg, gélule

    Tour Hekla

    Adult with an staphylococcal prosthetic joint infection treated with debridement, antibiotics and implant retention (DAIR strategy)

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources